BELGRADE, Mont. , May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the Company's annual meeting of stockholders, originally

BELGRADE, Mont. , May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC ,

BELGRADE, Mont. , May 12, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into an amendment to its senior credit facility with affiliates of OrbiMed Advisors

First Quarter 2017 Highlights: Consolidated total revenue increased 5.3% to $22.1 million compared to first quarter 2016 revenue of $21.0 million Consolidated gross profit increased 10.1% to $15.5 million compared to first quarter 2016 gross profit of $14.1 million Consolidated gross margins

BELGRADE, Mont. , May 05, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, has established a record date for its 2017 annual meeting of stockholders.

BELGRADE, Mont. , May 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, announced that it will release its financial results for the First Quarter ended March 31st, 2017 , at the close of the

BELGRADE, Mont. , April 25, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has been named as the Montana Ambassador Business of the

BELGRADE, Mont. , April 05, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016

See footnote about the use of pro forma financial information Fourth Quarter 2016 Highlights: Consolidated total revenue increased 9.9% to a record $24.5 million compared to fourth quarter 2015 revenue of $22.3 million Consolidated gross profit increased 17.4% to $17.5 million compared to fourth

BELGRADE, Mont. , March 01, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2016 ,